Skip to main content

Table 6 Incidence of ADR in different drug-pair combinations

From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

COVID-19 drug pair ADR
Atazanavir–hydroxychloroquine 55 (25.3%)
Lopinavir/ritonavir–hydroxychloroquine 34 (15.7%)
Lopinavir/ritonavir–interferon beta-1b 5 (2.3%)
Atazanavir–favipiravir 1 (0.5%)
Lopinavir/ritonavir–chloroquine 1 (0.5%)
  1. ADR is reported as n (%), where % is calculated by taking ADR/patient with ADR